Related references
Note: Only part of the references are listed.Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
Gunavanthi D. Boorgula et al.
FRONTIERS IN PHARMACOLOGY (2021)
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile
Vianney Tuloup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis
Mohammad Javad Nasiri et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
Takanori Asakura et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Non-tuberculous mycobacterial pulmonary disease
Steven Cowman et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections
Jennifer A. Shulha et al.
MAYO CLINIC PROCEEDINGS (2019)
Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease
Hyung-Jun Kim et al.
BMC PULMONARY MEDICINE (2019)
The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study
Jun-ichi Kadota et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Clinical characteristics and treatment outcomes of pleural effusions in patients with nontuberculous mycobacterial disease
Sojung Park et al.
RESPIRATORY MEDICINE (2017)
Predictive factors for a one-year improvement in nontuberculous mycobacterial pulmonary disease: An 11-year retrospective and multicenter study
Gilbert Cadelis et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease
Claire M. Ellender et al.
RESPIROLOGY (2016)
Rifabutin: where do we stand in 2016?
Yoann Crabol et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease
Kohei Fujita et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Multidrug-resistant tuberculosis may be nontuberculous mycobacteria
Abdolrazagh Hashemi Shahraki et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)
Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease
Hitoshi Shimomura et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2015)
The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease
Yutaka Ito et al.
BMC INFECTIOUS DISEASES (2014)
Microbiological Features and Clinical Relevance of New Species of the Genus Mycobacterium
Enrico Tortoli
CLINICAL MICROBIOLOGY REVIEWS (2014)
Management of nontuberculous mycobacterial infection in the elderly
Mehdi Mirsaeidi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2014)
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy
Kyung-Wook Jo et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2014)
Highlight on Advances in Nontuberculous Mycobacterial Disease in North America
Mehdi Mirsaeidi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment
Jakko van Ingen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Experience with rifabutin replacing rifampin in the treatment of tuberculosis
D. J. Horne et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Treatment Outcome of Combination Therapy Including Clarithromycin forMycobacterium aviumComplex Pulmonary Disease
Eun Young Kim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
LANCET (2008)
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy
P. A. Jenkins et al.
THORAX (2008)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease
Yoshihiro Kobashi et al.
RESPIRATORY MEDICINE (2007)
Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease
Phung K. Lam et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
CA Benson et al.
CLINICAL INFECTIOUS DISEASES (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Rifampin and Rifabutin drug interactions - An update
CK Finch et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex
DE Griffith et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
